Middle dose antigen of LYB005 with A01B adjuvant

BIOLOGICAL2 trials

Sponsors

Guangzhou Patronus Biotech Co., Ltd.

Conditions

Respiratory Syncytial Virus InfectionRespiratory Syncytial Virus Infection Prevention

Phase 1

Safety and Immunogenicity of the Recombinant Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 18 Years and Older

Active, not recruitingNCT06904222

Guangzhou Patronus Biotech Co., Ltd.Respiratory Syncytial Virus Infection

Start: 2025-04-15End: 2026-08-31Target: 90Updated: 2025-08-22

Phase 2

A Study to Evaluate the Immunogenicity and Safety of a Recombinant Respiratory Syncytial Virus Vaccine in Older Adults Aged 60 Years and Older

Active, not recruitingNCT07208461

Guangzhou Patronus Biotech Co., Ltd.Respiratory Syncytial Virus Infection Prevention

Start: 2025-10-21End: 2026-12-01Target: 700Updated: 2026-02-11